Is Organogenesis Holdings Inc. (ORGO) a good stock to buy?

Olyth's institutional analysis of ORGO reveals an Altman Z-Score of 2.82 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.56B most recent), help investors decide if ORGO fits their risk profile.

What is the current P/E ratio for ORGO?

As of the latest trading session, Organogenesis Holdings Inc. (ORGO) has a trailing P/E ratio of 7.68.

Who is the CEO of Organogenesis Holdings Inc.?

The current Chief Executive Officer of Organogenesis Holdings Inc. is Gary S. Gillheeney.

What was ORGO's revenue for the last 5 years?

According to its latest income statements, Organogenesis Holdings Inc. reported annual revenues of $0.56B (2025), $0.48B (2024), $0.43B (2023), $0.45B (2022), $0.47B (2021) respectively.

Does ORGO pay a dividend?

Organogenesis Holdings Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does ORGO have?

In its latest reporting period, Organogenesis Holdings Inc. generated $-0.02B in Free Cash Flow against a total debt load of $0.13B.

What is the Price-to-Book (P/B) ratio of Organogenesis Holdings Inc.?

The Price-to-Book (P/B) ratio for Organogenesis Holdings Inc. (ORGO) is currently 0.66.

What is the Price-to-Sales (P/S) ratio of ORGO?

Based on trailing twelve-month data, Organogenesis Holdings Inc. (ORGO) trades at a Price-to-Sales (P/S) ratio of 0.51.

What is Organogenesis Holdings Inc.'s Return on Equity (ROE)?

Organogenesis Holdings Inc. (ORGO) has a Return on Equity (ROE) of 9.56%, representing its profitability relative to shareholder equity.

ORGO

Organogenesis Holdings Inc. · Healthcare

2.48

10.49%(+0.23)

Market Open

Last Updated: — ET

52W L: $2.2152W H: $7.08

$2.46

CHG-0.17 (-6.27%)

H$3.17

L$2.21

VOL14M

ORGO (1h)

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

869

IPO Date

2017-01-05

Beta

1.48

Websiteorganogenesis.com↗

ORGO

Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

SG Americas Securities LLC Acquires 376,623 Shares of Organogenesis $ORGO

Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript